SIRT7 and neoplasm: In addition, the combination of the knockdown of SIRT7 and anti-PD-1 antibody treatment could induce more infiltration of CD8+T cells and GzmB-positive CD8+T cells in the implanted tumor (Fig. 6i–k; Supplementary Fig. S8f), indicating that the combination treatment approach triggered more prominent activation of anti-tumor immunity.